Xerys Invest
Xerys Invest is a French private equity firm founded in 2009, specializing in supporting entrepreneurs and management teams at all stages of growth, from venture capital to maturity, with a focus on sustainable value creation. The firm manages over 200 million euros in assets and invests mainly in healthcare, life sciences, renewable energy, and greentech sectors.
Key facts
Recent exits
Coverage notes
1 fund tracked, 9 portfolio companies (6 active · 3 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Xerys Invest has raised, with its portfolio companies. Hand-checked from public filings.
Xerys Capital FranceGrowth2014 · 12yr€100M6 active · 3 realized
Unrealized
6 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Advanced BioDesign | Healthcare | France | 2016 |
| AlzProtect | Healthcare | France | 2017 |
| Biolog-id | Healthcare | France | 2022 |
| Herow | TMT | France | 2015 |
| Powidian | Energy | France | 2016 |
| Skytech | TMT | France | 2013 |
Realized
3 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| 7Hugs Labs | Software | France | 2017 | 2020 | Trade Sale | – | |
| Cryo Pur | Healthcare | France | 2015 | 2022 | Trade Sale | – | |
| Optionizr | TMT | France | 2018 | 2025 | Trade Sale | – |
Saved GPs appear in your watchlist, one click from your workspace.
About Xerys Invest
Xerys Invest is a French private equity firm with €200 million of assets under management, founded in 2009 and headquartered in Paris. The firm specialises in supporting entrepreneurs and management teams at all stages of growth, from venture capital to maturity, with a focus on sustainable value creation across multi-stage investment vehicles.
Investment thesis
Xerys Invest targets French and selectively European companies across the company lifecycle, deploying venture capital (early-stage), growth equity (scaling) and selective buyout positions with the multi-stage mandate enabling flexibility across distinct return profiles. Sector focus spans the broad coverage typical of multi-strategy platforms, with the firm emphasising operational partnership with founder-operator management teams across the holding period.
Recent activity
Recent realised exits include Cryo Pur (healthcare, 2022), reflecting selective distribution activity. The platform tracks a single dedicated fund vehicle, 4 active portfolio companies and 4 realised exits across the multi-stage French programme. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.